OnKure Therapeutics, Inc. (OKUR NASDAQ) stock market data APIs
$2.499
-0.09(-3.6%)
as of September 18, 2025
Try our APIs with
free plan!
OnKure Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Prev. Close
2.499
Open
2.4109
High
2.5493
Low
2.4109
52 wk Range
1.7-19.999
Market Cap
32 337 K
Shares Outstanding
12 843 K
EPS
-1.14
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with OnKure Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OnKure Therapeutics, Inc. data using free add-ons & libraries
Get OnKure Therapeutics, Inc. Fundamental Data
OnKure Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -62 842 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -1.248
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OnKure Therapeutics, Inc. News
New
OnKure Therapeutics Inc-A (NASDAQ:OKUR) Reports Q2 2025 Earnings Beat with Narrower-Than-Expected Loss
OnKure Therapeutics Inc-A (NASDAQ:OKUR [https://www.chartmill.com/stock/quote/OKUR]) reported its second-quarter 2025 financial results, posting an earnings per share (EPS) of -$1.14, which outperform...
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company’...
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
